investment analyst coverage
Investment Banks Initiate Coverage of Tempus, Grail
Analysts from BTIG highlighted Tempus' artificial intelligence-based genomics, while Canaccord Genuity underscored Grail's strength in pan-cancer screening.
Craig-Hallum Initiates Coverage of Veracyte With Buy Rating, $45 Price Target
The investment bank views the company as a promising target with a strong track record and prospects for expansion into new, under-penetrated markets.
Investment Bank Evercore ISI Initiates Coverage of Bio-Techne With Outperform Rating
The investment bank said Bio-Techne is a premium growth asset with a strong core business and growth verticals.
UBS Initiates Coverage of Myriad Genetics With Neutral Rating
Analysts noted that while continued double-digit growth appears unsustainable in the near term, risks related to UnitedHealthcare's decision on pharmacogenetic testing appear limited.
Wolfe Research Upgrades Danaher to Outperform
The upgrade is based on the firm's improving growth, more reasonable valuations, and its ability to deploy capital.
Oct 16, 2024
UBS Initiates Coverage of Veracyte With Buy Rating
Oct 15, 2024
Barclays Upgrades Revvity to Overweight
Sep 5, 2024
Craig-Hallum Upgrades QuidelOrtho to Buy
May 1, 2024
Craig-Hallum Upgrades CareDx to Buy
May 11, 2023